Circio: Funding, Investors & Team (Sep 2026)
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging diseases. Their goal is to use vector-based technology to create a new type of circRNA medicines. They are working with Prof Michael Uhlin and his team at the Karolinska Institutet in Stockholm to develop advanced RNA therapeutics. Additionally, the company is conducting two collaborative clinical trials for a mutant RAS cancer vaccine program in the USA and Norway. They are also exploring financing options for a phase 2 study of ONCOS-102, a genetically modified oncolytic adenovirus.
Circio has raised $34.0M across 3 funding rounds on record, the most recent an undisclosed round of $31.5M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Circio Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Circio Funding Rounds
Circio raised $2.3M in an undisclosed round announced in Nov 2024.
6 months later, an undisclosed round of $240k was announced in May 2025.
1.1 years later, an undisclosed round of $31.5M was announced in Jun 2026.
Circio Founders and Leadership Team
Contact details for the Circio team: 1 of 2 have an email address on file.
Start 14-day free trial →Circio Funding Compared to Other Biotechnology Startups
Circio's latest round of $31.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Circio in Biotechnology and Oslo
Companies Similar to Circio
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on…
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who…
Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These…
Circio Funding FAQs
What does Circio do?
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging diseases. Their goal is to use vector-based technology to create a new type of circRNA medicines. They are working with Prof Michael Uhlin and his team at the Karolinska Institutet in Stockholm to develop advanced RNA therapeutics. Additionally, the company is conducting two collaborative clinical trials for a mutant RAS cancer vaccine program in the USA and Norway. They are also exploring financing options for a phase 2 study of ONCOS-102, a genetically modified oncolytic adenovirus.
How much funding has Circio raised?
Circio has raised $34.0M across 3 rounds on record. The most recent is an undisclosed round of $31.5M announced in Jun 2026.
When did Circio last raise funding?
Circio's most recent funding round on record is an undisclosed round of $31.5M, announced in Jun 2026.
Who founded Circio?
FundedIQ lists Erik Digman (Founder), Gustav Gaudernack (Founder) at Circio.
Where is Circio headquartered?
Circio is based in Oslo, Norway.
How many employees does Circio have?
Circio is in the 11-50 employee band.
How does Circio's funding compare to other Biotechnology startups?
Circio's latest round of $31.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Circio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Circio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.